Iron Management in Hemodialysis Patients

Guideline Recommendations

The National Kidney Foundation (NKF) strongly recommends intravenous iron for hemodialysis patients with iron deficiency, with a strength of evidence level not specified 1
Patients with active GI symptoms, such as coffee ground emesis or melena, may be exempt from oral iron due to potential exacerbation, as per the Crohn's and Colitis guidelines 2

Iron deficiency is a common cause of severe anemia in hemodialysis patients, characterized by low hemoglobin levels, with a prevalence not specified 1
Diagnostic criteria for iron deficiency include TSAT < 20% and ferritin < 100 ng/mL (inflammatory) or < 30 ng/mL (non-inflammatory), as stated by the NKF and other authorities 1, 3
The following table summarizes the diagnostic criteria for iron deficiency:
Parameter Threshold
TSAT < 20%
Ferritin < 100 ng/mL (inflammatory) or < 30 ng/mL (non-inflammatory)
Initiate iron therapy when TSAT is ≤20% and serum ferritin is ≤100 ng/mL, with a strength of evidence level not specified, as recommended by the American Journal of Kidney Diseases 1
Consider iron supplementation even with higher ferritin levels (up to 500 ng/mL) if TSAT remains ≤20% and anemia persists, with a strength of evidence level not specified, as recommended by Drugs 4

Parameter	Threshold
TSAT	< 20%
Ferritin	< 100 ng/mL (inflammatory) or < 30 ng/mL (non-inflammatory)

Administer 100-125 mg IV iron at each hemodialysis session for 8-10 doses (total 800-1000 mg), with a strength of evidence level not specified, as recommended by the NKF 1
Both iron sucrose and ferric gluconate do not require a test dose, unlike iron dextran, according to the Kidney International Supplements guidelines, with a strength of evidence level not specified 5
Initial dosing of 100-125 mg IV at each hemodialysis session for 8-10 doses (total 800-1000 mg) is recommended for adult hemodialysis patients, with a strength of evidence level not specified, as suggested by the American Journal of Kidney Diseases 1
Maintenance dosing of 25-125 mg IV weekly once target levels are achieved is suggested, with a strength of evidence level not specified, by the American Journal of Kidney Diseases 1
Hold IV iron when ferritin exceeds 700-800 ng/mL or TSAT exceeds 40-50%, with a strength of evidence level not specified, as recommended by the American Journal of Kidney Diseases 1

Aim for hemoglobin levels of 11-12 g/dL (hematocrit 33-36%) in hemodialysis patients, with a strength of evidence level not specified, as recommended by the NKF 1
Avoid targeting higher hemoglobin levels due to increased cardiovascular risks, with a strength of evidence level not specified, as stated by Drugs 4
Complete blood count with red cell indices, absolute reticulocyte count, serum ferritin level, transferrin saturation (TSAT), and vitamin B12 and folate levels are recommended for patients with severe anemia starting hemodialysis, with a strength of evidence level not specified, as suggested by the American Journal of Kidney Diseases 1, 6

Monitor iron status (TSAT and ferritin) every 3 months during maintenance therapy, with a strength of evidence level not specified, as recommended by the American Journal of Kidney Diseases 1
Reassess hemoglobin and iron studies 4-8 weeks after completing IV iron therapy, with an expected increase in hemoglobin by 1-2 g/dL within 4-8 weeks, with a strength of evidence level not specified 7
Consider functional iron deficiency when TSAT is <20% despite ferritin >100 ng/mL, especially in patients receiving ESA therapy, with a strength of evidence level not specified, as reported by the American Journal of Kidney Diseases 1
High ferritin in ESRD often reflects inflammation rather than adequate iron stores, and functional iron deficiency can occur despite normal or elevated ferritin levels, with a strength of evidence level not specified, as reported by 8, 4

Start ESA therapy concurrently with iron supplementation in patients with severe anemia, with a strength of evidence level not specified, as recommended by the American Journal of Kidney Diseases 1
Consider a trial of IV iron alone first if anemia is mild to moderate, with a strength of evidence level not specified, according to Kidney International 6
If no increase in hemoglobin after one month of appropriate ESA dosing, evaluate for ongoing blood loss, iron deficiency, infection/inflammation, malnutrition, and hyperparathyroidism, with a strength of evidence level not specified, as recommended by Kidney International 6